The High Cost of Healing: Revlimid’s Price and Its Impact on Patients

The pain woke me abruptly early one misty February morning in 2023, with an intensity I had never felt before. It felt as if my side was being stabbed, a sharp escalation from the dull ache I had been experiencing for weeks. The discomfort felt similar to a bad runner’s cramp, but it was now so severe I had to brace against the wall to stand.

At the emergency room, a doctor pulled me into a private space to share the results of a scan. There were lesions on my hip bones and sternum—symptoms of multiple myeloma, a type of blood cancer that destroys bone.

The doctor said, “Cancer.” The words brought a new level of fear as I learned there were numerous lesions throughout my body, along with bone fractures. There is no known cure for this disease.

After leaving the ER, I sat outside. In desperation, I searched for more information online. It was then that I uncovered older statistics indicating an average lifespan of three to five years for new patients. This information distressed me until I discovered it was outdated, thanks to advancements in treatment.

The treatments now available often include Revlimid, a derivative of the once notorious drug thalidomide. I was familiar with its dark past, knowing it as a drug that caused severe birth defects when prescribed to pregnant women in the mid-20th century. It was banned globally after thousands of children were born with deformities.

Now revived as a treatment for cancer, Revlimid has extended countless lives, including my own. However, it comes at a staggering price—nearly $1,000 per daily pill, a stark contrast to the 25-cent production cost.

This high cost places a substantial burden on patients and contributes to rising insurance premiums. As someone who has studied the high costs in U.S. healthcare, I was taken aback by the price of Revlimid. Despite my background, the financial burden of swallowing a capsule worth as much as a significant purchase was considerable.

The price of Revlimid has increased 26 times since its introduction. This price trajectory reflects strategic actions by Celgene, the drugmaker, and sheds light on the broader challenge of drug pricing in the U.S.

This story also includes the journey of Beth and Ira Wolmer, a couple battling multiple myeloma. On a journey to save Ira, Beth confronted the challenges of treatment costs and fought for every possible option, connecting with influential figures such as Dr. Bart Barlogie in their search for a solution.

In the 1990s, Dr. Judah Folkman and researcher Robert D’Amato explored the potential of thalidomide analogs to treat cancer through impeding blood vessel growth. Against the odds, thalidomide reemerged as a powerful cancer therapeutic, despite its controversial history.

Celgene capitalized on this breakthrough. What started as inexpensive treatments quickly became lucrative business opportunities. Celgene fought to keep its patents strong and competition at bay, leveraging regulatory mechanisms to maintain market dominance and raise prices.

The company saw massive financial success, transforming thalidomide derivatives into billion-dollar entities, yet the ongoing price hikes and market exclusivity kept generics away for years. Celgene’s strategies illustrate how drug companies can sustain high costs through complex licensing agreements and patents.

Eventually, patients like myself found Revlimid to be vital, though not without its financial and health-related challenges. Trade-offs included severe side effects and ever-looming threats of relapse. Many patients faced limitations or debt due to medication costs, while drug companies thrived financially.

The conclusion of this journey intertwines with reflections on the battle against cancer—not only the fight within the body but also against the external system of drug pricing. Facing ongoing treatment and costs, the sentiment of unfinished struggle prevails.